Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
11.75
-0.11 (-0.93%)
Apr 25, 2025, 12:23 PM EDT - Market open
Mesoblast Revenue
Mesoblast had revenue of $3.16M in the half year ending December 31, 2024, a decrease of -7.77%. This brings the company's revenue in the last twelve months to $5.67M, down -24.07% year-over-year. In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%.
Revenue (ttm)
$5.67M
Revenue Growth
-24.07%
P/S Ratio
257.93
Revenue / Employee
$77,671
Employees
73
Market Cap
1.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
MESO News
- 8 days ago - Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives - GlobeNewsWire
- 21 days ago - Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin' and Not Subject to U.S. Tariffs - GlobeNewsWire
- 22 days ago - Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure - GlobeNewsWire
- 25 days ago - First Three Children to Commence Treatment With Ryoncil® - GlobeNewsWire
- 4 weeks ago - Ryoncil® is Now Available for Purchase in the United States - GlobeNewsWire
- 6 weeks ago - Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States - GlobeNewsWire
- 6 weeks ago - Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall - GlobeNewsWire
- 7 weeks ago - Mesoblast Limited (MESO) Q2 2025 Earnings Call Transcript - Seeking Alpha